Merck’s KEYTRUDA (pembrolizumab) Superior to Brentuximab Vedotin (BV), a Standard of Care, in Patients With Classical Hodgkin Lymphoma (cHL) in…
stemadminAdult Stem CellsNo comments

KENILWORTH, N.J.--(BUSINESS WIRE)--May 13, 2020-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-204, a Phase 3 trial evaluating KEYTRUDA, Mercks anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In this pivotal study, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), one of the dual primary endpoints. KEYTRUDA reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.48-0.88; p=0.00271]) and showed a median PFS of 13.2 months compared with 8.3 months for patients treated with brentuximab vedotin (BV), a current standard of care in this patient population

Read more
Altered Bone Marrow Microenvironment Induces Defect of Hematopoietic Stem Cells in -thalassemia – Hematology Advisor
stemadminAdult Stem CellsNo comments

Impairedhematopoietic stem cell (HSC) self-renewal in -thalassemia is induced by an altered bonemarrow microenvironment and correction of HSC-stromal niche crosstalk rescuesthalassemic HSC function by in vivoreactivation of PTH signaling, according to a study published in Blood. HSCs in the adult hematopoietic system are regulated bysignals from the bone marrow niche; however, few studies have robustlyinvestigated malignancies in which the homeostasis of bone marrow iscompromised when HSCs are not directly affected. In -thalassemia, ineffective erythropoiesis and secondaryalterations such as abnormal regulation of bone metabolism, iron overload, andhormonal factors induce changes in the bone marrow homeostasis with a potentialeffect on HSC-niche interaction

Read more
Stemline Slated for Acquisition by Menarini in Deal Worth Up to $677M – Xconomy
stemadminAdult Stem CellsNo comments

XconomyNew York Stemline Therapeutics, whose drug for a rare, aggressive type of acute leukemia was approved by the FDA about 18 months ago, has signed an acquisition deal with Italian biopharma Menarini Group. Stemline (NASDAQ: STML), a New York-based company, developed the first FDA-approved drug for blastic plasmacytoid dendritic cell neoplasm, or BPDCN.

Read more
Rituximab Offers No Extra Benefit to Induction Chemo in ALL – Medscape
stemadminAdult Stem CellsNo comments

Adding the anti-CD20 monoclonal antibody rituximab (various brands) to induction chemotherapy in patients with B-precursor acute lymphoblastic leukaemia (B-ALL) does not improve outcomes, UK researchers have found in a primary analysis of phase 3 trial data. However, a separate examination of findings from the same study may nevertheless point to an update to the genetic classification for the disease that could help in creating an overall combined clinical and genetic risk score

Read more
Weekly pick of brain tumour research news from around the world – Brain Tumour Research
stemadminAdult Stem CellsNo comments

09 May 2020 NF1 affects about one in every 3,000 people. It is caused by any one of a variety of mutations in the NF1 gene and is something of great interest to our Plymouth research centre. They will no doubt be keen to read about new targets for childhood brain tumours identified a study which indicates that the growth of neurofibromatosis type 1 (NF1) brain tumours is driven by nearby noncancerous neurons and immune cells, and that targeting these immune cells could slow tumour growth.

Read more

Theme: Illdy.